XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Other Financial Information
 9 Months Ended
Sep. 29, 2024
Other Financial Information [Abstract]  
Other Financial Information Other Financial Information
A. Inventories
The following summarizes the components of Inventories:
(MILLIONS)September 29,
2024		December 31, 2023
Finished goods$3,280 $3,495 
Work-in-process7,267 5,688 
Raw materials and supplies1,174 1,007 
Inventories(a)
$11,721 $10,189 
Noncurrent inventories not included above(b)
$2,765 $4,568 
(a)The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, supply recovery and network strategy.
(b)Included in Other noncurrent assets. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See Note 2A. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
B. Other Current Liabilities
Other current liabilities include, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $375 million as of September 29, 2024 and $2.0 billion as of December 31, 2023.
C. Supplier Finance Program Obligation
We maintain voluntary supply chain finance agreements with several participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Pfizer to these financial institutions. As of September 29, 2024 and December 31, 2023, respectively, $628 million and $791 million of our trade payables to suppliers who participate in these financing arrangements were outstanding.